<DOC>
	<DOCNO>NCT03074331</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy , safety , tolerability treatment sofosbuvir ( SOF ) /velpatasvir ( VEL ) fix dose combination ( FDC ) 12 week adults chronic hepatitis C virus ( HCV ) infection .</brief_summary>
	<brief_title>Sofosbuvir/Velpatasvir Fixed Dose Combination 12 Weeks Adults With Chronic Hepatitis C Virus ( HCV ) Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Key Willing able provide write informed consent HCV RNA detect screen Chronic HCV infection ( ≥ 6 month ) document medical history liver biopsy Classification treatment naïve treatment experience . Approximately 20 % may treatmentexperienced . Cirrhosis determination ( approximately 20 % may cirrhosis ) Females childbearing potential must negative urine pregnancy test Screening Day 1 prior enrollment . Male individual female individual childbearing potential engage heterosexual intercourse must agree use protocol specify method ( ) contraception describe study protocol Lactating female must agree discontinue nursing study drug administer Adults must able comply dose instruction study drug administration able complete study schedule assessment Key Current prior history follow : Clinicallysignificant illness ( HCV ) major medical disorder may interfere individual 's treatment , assessment compliance protocol Clinical hepatic decompensation ( ie , ascites , encephalopathy variceal hemorrhage ) Liver transplantation Hepatocellular carcinoma ( HCC ) ( determine appropriate image screen cirrhosis ) current malignancy patient receive treatment may interfere individual 's treatment , assessment compliance protocol . Screening laboratory parameter outside define threshold Prior exposure HCV NS5A inhibitor Pregnant nursing female Infection hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV ) Use prohibit concomitant medication describe study protocol Known hypersensitivity VEL , SOF , formulation excipients Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>